ADAPTIVE BIOTECHNOLOGIES CORPORATION Capital Expenditures
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Capital Expenditures of $1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.18M, a 80.76% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $796.00K, a 36.78% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $636.00K, a 695.00% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $409.00K, a 18.90% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for fiscal 2025 was $2.96M, a 19.24% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for fiscal 2024 was $3.66M, a 65.75% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for fiscal 2023 was $10.70M, a 34.57% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire property, plant, and equipment for fiscal 2022 was $16.35M, a 73.52% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.98M 10-Q · filed 2026-08-04 | $2.62M derived: sum of 3 quarters · filed 2026-08-04 | $3.02M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $796.00K 10-Q · filed 2026-05-05 | $1.43M derived: sum of 2 quarters · filed 2026-05-05 | $1.84M derived: sum of 3 quarters · filed 2026-05-05 | $2.50M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $636.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.04M derived: sum of 2 quarters · filed 2026-02-26 | $1.70M derived: sum of 3 quarters · filed 2026-08-04 | $2.96M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $409.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.06M derived: sum of 2 quarters · filed 2026-08-04 | $2.32M 10-Q · filed 2025-11-05 | $2.40M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $655.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.91M 10-Q · filed 2026-08-04 | $1.99M derived: sum of 3 quarters · filed 2026-08-04 | $2.34M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-05 | $1.34M derived: sum of 2 quarters · filed 2026-05-05 | $1.68M derived: sum of 3 quarters · filed 2026-05-05 | $3.41M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $424.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.15M derived: sum of 3 quarters · filed 2026-02-26 | $3.66M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.07M derived: sum of 2 quarters · filed 2025-11-05 | $3.58M 10-Q · filed 2025-11-05 | $4.88M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.24M 10-Q · filed 2025-08-05 | $4.54M derived: sum of 3 quarters · filed 2026-02-26 | $7.32M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $1.51M 10-Q · filed 2025-05-01 | $2.81M derived: sum of 2 quarters · filed 2026-02-26 | $5.59M derived: sum of 3 quarters · filed 2026-02-26 | $9.28M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.08M derived: sum of 2 quarters · filed 2026-02-26 | $7.77M derived: sum of 3 quarters · filed 2026-02-26 | $10.70M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.47M derived: sum of 2 quarters · filed 2024-11-07 | $9.40M 10-Q · filed 2024-11-07 | $11.94M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $6.62M 10-Q · filed 2024-08-01 | $9.16M derived: sum of 3 quarters · filed 2025-03-03 | $14.60M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $2.92M 10-Q · filed 2024-05-07 | $5.47M derived: sum of 2 quarters · filed 2025-03-03 | $10.90M derived: sum of 3 quarters · filed 2025-03-03 | $16.20M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $7.97M derived: sum of 2 quarters · filed 2025-03-03 | $13.27M derived: sum of 3 quarters · filed 2025-03-03 | $16.35M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $5.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $10.73M derived: sum of 2 quarters · filed 2023-11-09 | $13.81M 10-Q · filed 2023-11-09 | $23.05M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $8.38M 10-Q · filed 2023-08-02 | $17.62M derived: sum of 3 quarters · filed 2024-02-29 | $32.24M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $3.08M 10-Q · filed 2023-05-03 | $12.32M derived: sum of 2 quarters · filed 2024-02-29 | $26.94M derived: sum of 3 quarters · filed 2024-02-29 | $48.98M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $23.86M derived: sum of 2 quarters · filed 2024-02-29 | $45.91M derived: sum of 3 quarters · filed 2024-02-29 | $61.75M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $14.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $36.66M derived: sum of 2 quarters · filed 2022-11-03 | $52.50M 10-Q · filed 2022-11-03 | $61.87M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-06-30 | $22.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $37.88M 10-Q · filed 2022-08-03 | $47.25M derived: sum of 3 quarters · filed 2023-02-14 | $51.46M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-03-31 | $15.84M 10-Q · filed 2022-05-04 | $25.21M derived: sum of 2 quarters · filed 2023-02-14 | $29.42M derived: sum of 3 quarters · filed 2023-02-14 | $31.68M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2020-12-31 | $9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $13.58M derived: sum of 2 quarters · filed 2023-02-14 | $15.84M derived: sum of 3 quarters · filed 2023-02-14 | $18.80M 10-K · filed 2023-02-14 | |
| 2020-09-30 | $4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $6.47M derived: sum of 2 quarters · filed 2021-11-03 | $9.43M 10-Q · filed 2021-11-03 | $11.85M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $5.23M 10-Q · filed 2021-08-04 | $7.64M derived: sum of 3 quarters · filed 2022-02-15 | $11.07M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2020-03-31 | $2.96M 10-Q · filed 2021-05-05 | $5.38M derived: sum of 2 quarters · filed 2022-02-15 | $8.81M derived: sum of 3 quarters · filed 2022-02-15 | $10.33M derived: sum of 4 quarters · filed 2022-02-15 | |
| 2019-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $5.85M derived: sum of 2 quarters · filed 2022-02-15 | $7.37M derived: sum of 3 quarters · filed 2022-02-15 | $11.20M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $4.95M derived: sum of 2 quarters · filed 2020-11-10 | $8.78M 10-Q · filed 2020-11-10 | $11.28M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $5.35M 10-Q · filed 2020-08-10 | $7.85M derived: sum of 3 quarters · filed 2021-02-24 | $10.04M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $3.83M 10-Q · filed 2020-05-12 | $6.33M derived: sum of 2 quarters · filed 2021-02-24 | $8.52M derived: sum of 3 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $4.68M derived: sum of 2 quarters · filed 2021-02-24 | $6.30M 10-K · filed 2021-02-24 | $6.32M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.80M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $1.61M 10-Q · filed 2019-08-13 | ||||
| 2017-12-31 | $2.42M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |